Epizyme Company Profile (NASDAQ:EPZM)

About Epizyme

Epizyme logoEpizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company's segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. It develops small molecule inhibitors of other chromatin modifying proteins, or CMPs. Its lead product candidate, tazemetostat, is a selective inhibitor of the EZH2 HMT. It is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma, or NHL, and one Phase II study in adults and one Phase I study in children with certain genetically-defined solid tumors. It has programs in development, including a Phase I clinical trial of pinometostat, an inhibitor of the DOT1L HMT, for the treatment of children with MLL-r, an acute leukemia with genetic alterations of the MLL gene.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EPZM
  • CUSIP:
Key Metrics:
  • Previous Close: $12.80
  • 50 Day Moving Average: $11.32
  • 200 Day Moving Average: $10.03
  • 52-Week Range: $58,011,000.00 - $7.02
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.98
  • P/E Growth: 0.00
  • Market Cap: $742.54M
  • Outstanding Shares: 58,011,000
  • Beta: 2.24
Profitability:
  • Net Margins: -1,205.01%
  • Return on Equity: -41.56%
  • Return on Assets: -34.78%
Debt:
  • Current Ratio: 17.35%
  • Quick Ratio: 17.35%
Additional Links:
Companies Related to Epizyme:

Analyst Ratings

Consensus Ratings for Epizyme (NASDAQ:EPZM) (?)
Ratings Breakdown: 8 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.00 (95.31% upside)

Analysts' Ratings History for Epizyme (NASDAQ:EPZM)
Show:
DateFirmActionRatingPrice TargetDetails
11/28/2016WedbushReiterated RatingOutperform$22.00View Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyView Rating Details
11/6/2016HC WainwrightReiterated RatingBuyView Rating Details
10/7/2016Leerink SwannReiterated RatingOutperformView Rating Details
6/20/2016Cowen and CompanyReiterated RatingBuyView Rating Details
6/20/2016MizuhoReiterated RatingBuy$18.00View Rating Details
6/20/2016Royal Bank Of CanadaReiterated RatingOutperform$26.00View Rating Details
4/5/2016Citigroup Inc.Initiated CoverageBuy$17.00View Rating Details
12/22/2015SunTrust Banks, Inc.Initiated CoverageBuy$21.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Epizyme (NASDAQ:EPZM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017        
11/3/2016Q3($0.60)($0.42)$6.60 millionViewListenView Earnings Details
8/8/2016Q2($0.52)($0.49)ViewListenView Earnings Details
5/9/2016Q1($0.53)($0.41)ViewListenView Earnings Details
3/9/2016Q415($0.65)($0.53)ViewListenView Earnings Details
11/9/2015Q315($0.59)($0.56)$5.42 millionViewListenView Earnings Details
8/6/2015Q215($0.70)($0.63)$2.45 millionViewListenView Earnings Details
4/28/2015Q115($0.99)($1.75)$5.63 millionViewN/AView Earnings Details
3/12/2015Q414($0.53)($0.44)$10.10 million$10.35 millionViewListenView Earnings Details
11/6/2014Q314($0.55)($0.58)$7.00 million$8.20 millionViewN/AView Earnings Details
8/13/2014Q214($0.50)($0.40)$7.59 million$9.50 millionViewN/AView Earnings Details
5/13/2014Q114($0.47)($0.22)$8.48 millionViewN/AView Earnings Details
2/27/2014Q413($0.22)$0.52$9.00 million$36.32 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Epizyme (NASDAQ:EPZM)
Current Year EPS Consensus Estimate: $-1.98 EPS
Next Year EPS Consensus Estimate: $-2.57 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.63)($0.42)($0.51)
Q2 20164($0.68)($0.45)($0.55)
Q3 20163($0.64)($0.50)($0.57)
Q4 20163($0.73)($0.55)($0.63)
Q1 20172($0.63)($0.61)($0.62)
Q2 20172($0.64)($0.64)($0.64)
Q3 20172($0.66)($0.64)($0.65)
Q4 20172($0.68)($0.65)($0.67)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Epizyme (NASDAQ:EPZM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Epizyme (NASDAQ:EPZM)
Insider Ownership Percentage: 25.40%
Institutional Ownership Percentage: 79.98%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Andrew E SingerCFOSell1,013$12.04$12,196.52View SEC Filing  
12/9/2016Andrew E SingerCFOSell1,013$11.03$11,173.39View SEC Filing  
11/9/2016Andrew E SingerCFOSell1,013$10.40$10,535.20View SEC Filing  
10/10/2016Andrew E SingerCFOSell1,013$9.72$9,846.36View SEC Filing  
9/9/2016Andrew E SingerCFOSell1,013$7.55$7,648.15View SEC Filing  
8/9/2016Andrew E SingerCFOSell1,013$9.05$9,167.65View SEC Filing  
8/1/2016Robert A CopelandInsiderSell4,000$10.37$41,480.00View SEC Filing  
7/11/2016Andrew E SingerCFOSell1,013$10.36$10,494.68View SEC Filing  
7/5/2016Robert A CopelandInsiderSell4,000$10.03$40,120.00View SEC Filing  
6/9/2016Andrew E SingerCFOSell1,013$12.49$12,652.37View SEC Filing  
4/12/2016Andrew E SingerCFOSell1,013$12.42$12,581.46View SEC Filing  
3/9/2016Andrew E SingerCFOSell1,006$9.33$9,385.98View SEC Filing  
2/29/2016Peter Tai-Ching HoInsiderBuy636$7.47$4,750.92View SEC Filing  
2/10/2016Andrew E. SingerCFOSell12,158$9.54$115,987.32View SEC Filing  
1/12/2016Bay City Capital Fund V Co-InvMajor ShareholderBuy555,555$9.00$4,999,995.00View SEC Filing  
1/12/2016David M MottDirectorBuy1,111,111$9.00$9,999,999.00View SEC Filing  
1/4/2016Robert A. CopelandinsiderSell4,185$15.58$65,202.30View SEC Filing  
12/30/2015Robert J. GouldDirectorSell32,108$18.01$578,265.08View SEC Filing  
12/9/2015Peter Tai-Ching HoInsiderBuy1,000$14.69$14,690.00View SEC Filing  
12/7/2015Robert A. CopelandinsiderSell4,185$13.82$57,836.70View SEC Filing  
11/9/2015Robert A. CopelandinsiderSell4,185$16.26$68,048.10View SEC Filing  
10/5/2015Robert A. CopelandinsiderSell4,185$14.43$60,389.55View SEC Filing  
9/8/2015Robert A. CopelandinsiderSell4,185$19.58$81,942.30View SEC Filing  
9/8/2015Robert J. GouldCEOSell60,000$19.86$1,191,600.00View SEC Filing  
7/6/2015Robert A CopelandInsiderSell8,371$22.86$191,361.06View SEC Filing  
7/6/2015Robert J GouldCEOSell60,000$23.22$1,393,200.00View SEC Filing  
5/5/2015Peter Tai-Ching HoInsiderBuy800$16.36$13,088.00View SEC Filing  
12/2/2014Peter Tai-Ching HoInsiderBuy1,000$21.17$21,170.00View SEC Filing  
11/17/2014Robert A CopelandEVPSell20,000$22.68$453,600.00View SEC Filing  
11/3/2014Robert A CopelandEVPSell20,000$25.47$509,400.00View SEC Filing  
11/3/2014Robert J GouldCEOSell30,000$24.95$748,500.00View SEC Filing  
10/7/2014Robert A CopelandEVPSell20,000$26.90$538,000.00View SEC Filing  
10/1/2014Robert J GouldCEOSell30,000$26.28$788,400.00View SEC Filing  
10/1/2014Stephen GarbaczInsiderSell868$27.06$23,488.08View SEC Filing  
9/22/2014Robert A CopelandEVPSell20,000$25.55$511,000.00View SEC Filing  
9/15/2014Eric HedrickInsiderSell2,000$28.67$57,340.00View SEC Filing  
9/4/2014Carl GoldfischerDirectorSell4,000$35.14$140,560.00View SEC Filing  
8/26/2014Bay City Capital LlcMajor ShareholderSell200,000$35.14$7,028,000.00View SEC Filing  
8/25/2014Bay City Capital LlcMajor ShareholderSell366,666$33.98$12,459,310.68View SEC Filing  
8/18/2014Robert A CopelandEVPSell10,830$36.07$390,638.10View SEC Filing  
8/15/2014Ryan D DrantMajor ShareholderSell4,061$36.54$148,388.94View SEC Filing  
8/4/2014Jason P RhodesCFOSell30,000$29.74$892,200.00View SEC Filing  
8/4/2014Robert A CopelandEVPSell20,000$29.42$588,400.00View SEC Filing  
7/15/2014Eric HedrickInsiderSell2,000$31.35$62,700.00View SEC Filing  
7/7/2014Jason P RhodesCFOSell30,000$32.74$982,200.00View SEC Filing  
7/1/2014Robert J GouldCEOSell30,000$31.53$945,900.00View SEC Filing  
6/23/2014Robert A CopelandEVPSell20,000$28.42$568,400.00View SEC Filing  
6/16/2014Eric HedrickInsiderSell2,000$26.42$52,840.00View SEC Filing  
6/16/2014Robert A CopelandEVPSell25,012$26.38$659,816.56View SEC Filing  
6/2/2014Robert J GouldCEOSell30,000$22.20$666,000.00View SEC Filing  
5/19/2014Robert CopelandEVPSell5,000$22.28$111,400.00View SEC Filing  
5/5/2014Jason RhodesCFOSell30,000$21.53$645,900.00View SEC Filing  
5/5/2014Robert CopelandEVPSell10,000$21.29$212,900.00View SEC Filing  
5/1/2014Robert GouldCEOSell30,000$21.91$657,300.00View SEC Filing  
4/28/2014Robert CopelandEVPSell13,800$20.73$286,074.00View SEC Filing  
4/7/2014Jason RhodesCFOSell25,000$20.05$501,250.00View SEC Filing  
4/7/2014Robert GouldCEOSell30,000$20.22$606,600.00View SEC Filing  
2/10/2014Celgene European Investment Comajor shareholderBuy340,000$29.25$9,945,000.00View SEC Filing  
1/6/2014Jason RhodesCFOSell10,000$20.19$201,900.00View SEC Filing  
12/16/2013Robert CopelandEVPSell4,600$21.21$97,566.00View SEC Filing  
12/2/2013Robert CopelandEVPSell5,000$20.70$103,500.00View SEC Filing  
11/15/2013M James Barrettmajor shareholderBuy406,500$19.68$7,999,920.00View SEC Filing  
6/5/2013David M MottDirectorBuy400,000$15.00$6,000,000.00View SEC Filing  
6/5/2013Venture Fund I L.P. AstellasMajor ShareholderBuy15,333$15.00$229,995.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Epizyme (NASDAQ:EPZM)
DateHeadline
biz.yahoo.com logoEPIZYME, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:EPZM)
biz.yahoo.com - February 8 at 5:32 PM
streetinsider.com logoEpizyme (EPZM) Elects Kevin Conroy to Board of Directors (NASDAQ:EPZM)
www.streetinsider.com - February 7 at 6:11 PM
finance.yahoo.com logoEpizyme Elects Kevin Conroy to its Board of Directors (NASDAQ:EPZM)
finance.yahoo.com - February 7 at 6:11 PM
News IconVolatility Spiking as Shares Ride the Wave: Epizyme, Inc. (NASDAQ:EPZM) - Davidson Register (NASDAQ:EPZM)
davidsonregister.com - February 6 at 10:06 PM
globenewswire.com logoEpizyme to Present at Upcoming Investor Conferences - GlobeNewswire (press release) (NASDAQ:EPZM)
globenewswire.com - February 2 at 10:33 PM
finance.yahoo.com logoEpizyme to Present at Upcoming Investor Conferences (NASDAQ:EPZM)
finance.yahoo.com - February 2 at 5:31 PM
News IconWhat are Research Firms Saying About Epizyme, Inc. (NASDAQ:EPZM)? - Aiken Advocate (NASDAQ:EPZM)
aikenadvocate.com - February 2 at 3:40 AM
realistinvestor.com logoEPS Projection Of Epizyme, Inc. (NASDAQ:EPZM) At $-0.68 - RealistInvestor.com (NASDAQ:EPZM)
www.realistinvestor.com - January 26 at 4:24 AM
News IconTechnical Indicator Review on Shares of Epizyme Inc. (EPZM) - Sherwood Daily (NASDAQ:EPZM)
sherwooddaily.com - January 24 at 10:43 PM
News IconEarnings in Full Force, Analysts Take Aim at Epizyme, Inc. (NASDAQ:EPZM) - Wall Street Beacon (NASDAQ:EPZM)
wsbeacon.com - January 24 at 10:43 PM
News IconPriming The Pump: Stock Volatility Spotted in Epizyme, Inc. (NASDAQ:EPZM) - Wall Street Beacon (NASDAQ:EPZM)
wsbeacon.com - January 23 at 5:20 PM
News IconStock Review: ADX, MA, RSI Numbers in View for Epizyme Inc. (EPZM) - Sherwood Daily (NASDAQ:EPZM)
sherwooddaily.com - January 18 at 10:25 PM
News IconWhat is the Sell-side Saying About Epizyme, Inc. (NASDAQ:EPZM)? - Aiken Advocate (NASDAQ:EPZM)
aikenadvocate.com - January 18 at 10:25 PM
News IconWill The Needle Move For Epizyme, Inc. (NASDAQ:EPZM) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:EPZM)
wsbeacon.com - January 17 at 3:29 PM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Epizyme, Inc. (NASDAQ:EPZM) - Prospect Journal (NASDAQ:EPZM)
prospectjournal.com - January 17 at 5:18 AM
News IconAverage Directional Index in Review for Epizyme Inc. (EPZM) - Springdale Times (NASDAQ:EPZM)
springdaletimes.com - January 17 at 5:18 AM
News IconEpiZyme Inc EPZM Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:EPZM)
www.bioportfolio.com - January 14 at 5:03 PM
finance.yahoo.com logoTherapeuticsMD's Rejoice Study Data Published in Journal (NASDAQ:EPZM)
finance.yahoo.com - January 12 at 5:29 PM
investornewswire.com logoEpizyme, Inc. (NASDAQ:EPZM) Records An Impact Score Of 100 - Investor Newswire (NASDAQ:EPZM)
www.investornewswire.com - January 11 at 5:35 PM
realistinvestor.com logoEpizyme, Inc. (NASDAQ:EPZM) EPS Estimate At $-0.68 - RealistInvestor.com (NASDAQ:EPZM)
www.realistinvestor.com - January 11 at 5:35 PM
finance.yahoo.com logoAlexion (ALXN) Files for Label Expansion of Soliris in U.S., EU (NASDAQ:EPZM)
finance.yahoo.com - January 11 at 5:35 PM
bizjournals.com logoNew England Venture Capital Association adds new board members (NASDAQ:EPZM)
www.bizjournals.com - January 10 at 5:56 PM
zacks.com logoPuma (PBYI) Expands Study Cohort for Lead Candidate PB272 (NASDAQ:EPZM)
www.zacks.com - January 9 at 5:49 PM
biz.yahoo.com logoEPIZYME, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:EPZM)
us.rd.yahoo.com - January 9 at 5:49 PM
News IconInteresting EPZM Put And Call Options For August 18th (NASDAQ:EPZM)
www.stockoptionschannel.com - January 6 at 5:35 PM
globenewswire.com logoEpizyme Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference - GlobeNewswire (press release) (NASDAQ:EPZM)
globenewswire.com - January 3 at 7:05 PM
finance.yahoo.com logoEpizyme Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference (NASDAQ:EPZM)
finance.yahoo.com - January 3 at 12:17 PM
News IconCommit To Purchase Epizyme At $10, Earn 27.3% Annualized Using Options (NASDAQ:EPZM)
www.stockoptionschannel.com - December 23 at 5:14 PM
News IconMoving Average Crossover Alert: Epizyme (EPZM) - Yahoo Sports (NASDAQ:EPZM)
sports.yahoo.com - December 20 at 10:02 AM
finance.yahoo.com logoMoving Average Crossover Alert: Epizyme (EPZM) (NASDAQ:EPZM)
finance.yahoo.com - December 20 at 10:02 AM
News IconInvestor Monitor: Narrowing in on Epizyme, Inc. (NASDAQ:EPZM ... - Marion Business Daily (NASDAQ:EPZM)
marionbusinessdaily.com - December 19 at 6:43 AM
News IconVC Score In Focus for Epizyme, Inc. (NASDAQ:EPZM) - The Business Journal (NASDAQ:EPZM)
belmontbusinessjournal.com - December 18 at 3:20 AM
News IconUpdate on Valuation Formula's For Epizyme, Inc. (NASDAQ:EPZM) - Marion Business Daily (NASDAQ:EPZM)
marionbusinessdaily.com - December 14 at 3:46 PM
News IconInsider Transaction: Epizyme Inc (NASDAQ:EPZM)'s EVP & CFO ... - Thorold News (NASDAQ:EPZM)
www.whatsonthorold.com - December 12 at 5:14 PM
News IconFollowing the Indicators: Reviewing Levels on Shares of Epizyme Inc. (EPZM) - StockTalk Daily (NASDAQ:EPZM)
stocktalkdaily.com - December 12 at 5:14 PM
News IconTop Stock With Upside & Growth Potential: Epizyme, Inc. (NASDAQ:EPZM) - Prospect Journal (NASDAQ:EPZM)
prospectjournal.com - December 12 at 5:14 PM
News IconStock Watch: Focusing in on Epizyme, Inc. (NASDAQ:EPZM) - The Business Journal (NASDAQ:EPZM)
belmontbusinessjournal.com - December 8 at 10:42 PM
insidermonkey.com logoShould You Add Epizyme Inc (EPZM) to Your Portfolio? (NASDAQ:EPZM)
www.insidermonkey.com - December 8 at 5:40 PM
realistinvestor.com logoEpizyme, Inc. (NASDAQ:EPZM) Is Expected To Post EPS Of $-0.68 - RealistInvestor.com (NASDAQ:EPZM)
www.realistinvestor.com - December 7 at 8:22 PM
News IconIndicator Level Review for Epizyme Inc. (EPZM) - StockTalk Daily (NASDAQ:EPZM)
stocktalkdaily.com - December 5 at 5:39 PM
News IconFollowing the Numbers on Shares of Epizyme, Inc. (NASDAQ:EPZM) - The Business Journal (NASDAQ:EPZM)
belmontbusinessjournal.com - November 30 at 5:04 PM
streetinsider.com logoEpizyme (EPZM) Updates on Clinical Programs; Tazemetostat Granted FDA Fast Track Designation in DLBCL (NASDAQ:EPZM)
www.streetinsider.com - November 29 at 5:29 PM
us.rd.yahoo.com logo6:30 am Epizyme announces fast track designation for Tazemetostat in DLBCL and provides solid tumor program update (NASDAQ:EPZM)
us.rd.yahoo.com - November 29 at 5:29 PM
us.rd.yahoo.com logoEpizyme Announces Fast Track Designation for Tazemetostat in DLBCL and Provides Solid Tumor Program Update (NASDAQ:EPZM)
us.rd.yahoo.com - November 29 at 5:29 PM
biz.yahoo.com logoEPIZYME, INC. Files SEC form 8-K, Other Events (NASDAQ:EPZM)
us.rd.yahoo.com - November 29 at 5:29 PM
us.rd.yahoo.com logoGood And Bad News from Epizyme; Wedbush Analyst Weighs In (NASDAQ:EPZM)
us.rd.yahoo.com - November 29 at 5:29 PM
News IconEpiZyme, Inc. EPZM Financial and Strategic SWOT Analysis Review Prices from USD $300 (NASDAQ:EPZM)
www.bioportfolio.com - November 25 at 10:05 AM
News IconStock Tracker: Trend Analysis on Epizyme Inc. (EPZM) - StockTalk Daily (NASDAQ:EPZM)
stocktalkdaily.com - November 24 at 6:55 AM
News IconMoving Average Watch for Epizyme Inc. (EPZM) - StockTalk Daily (NASDAQ:EPZM)
stocktalkdaily.com - November 22 at 8:05 AM
capitalcube.com logoEpizyme, Inc. :EPZM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016 (NASDAQ:EPZM)
www.capitalcube.com - November 21 at 5:07 PM

Social

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Where is Epizyme's stock going? Where will Epizyme's stock price be in 2017?

8 equities research analysts have issued 12 month target prices for Epizyme's stock. Their forecasts range from $17.00 to $39.00. On average, they anticipate Epizyme's stock price to reach $25.00 in the next year.

When will Epizyme announce their earnings?

Epizyme is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.

Who owns Epizyme stock?

Epizyme's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.08%), Palo Alto Investors LLC (5.23%), Deerfield Management Co. (2.76%), Foresite Capital Management II LLC (2.63%), Franklin Resources Inc. (2.00%) and State Street Corp (1.88%). Company insiders that own Epizyme stock include Andrew E Singer, Bay City Capital Fund V Co-Inv, David M Mott, Peter Tai-Ching Ho, Robert A Copeland and Robert J Gould.

Who sold Epizyme stock? Who is selling Epizyme stock?

Epizyme's stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Foresite Capital Management II LLC and Foresite Capital Management III LLC. Company insiders that have sold Epizyme stock in the last year include Andrew E Singer and Robert A Copeland.

Who bought Epizyme stock? Who is buying Epizyme stock?

Epizyme's stock was purchased by a variety of institutional investors in the last quarter, including Deerfield Management Co., State Street Corp, Palo Alto Investors LLC, J. Goldman & Co LP, Russell Investments Group Ltd., Dimensional Fund Advisors LP and Metropolitan Life Insurance Co. NY. Company insiders that have bought Epizyme stock in the last two years include Bay City Capital Fund V Co-Inv, David M Mott and Peter Tai-Ching Ho.

How do I buy Epizyme stock?

Shares of Epizyme can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Epizyme stock cost?

One share of Epizyme stock can currently be purchased for approximately $12.80.

Epizyme (NASDAQ:EPZM) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Earnings History Chart

Earnings by Quarter for Epizyme (NASDAQ:EPZM)

Dividend History Chart

Dividend Payments by Quarter for Epizyme (NASDAQ:EPZM)

Last Updated on 2/20/2017 by MarketBeat.com Staff